United States list prices are set with the expectation of confidential rebates negotiated between manufacturers and pharmacy benefit managers, and cash payers transact outside that structure
Another key driver is the diversification of therapeutic area, i.e., obesity and management of cardio metabolic risk to expand market opportunity
What to expect after stopping Wegovy
[DOI] [PubMed] [Google Scholar] 46.Ahrn B., Atkin S.L., Charpentier G., Warren M.L., Wilding J., Birch S., Holst A.G., Leiter L.A
Switching between cagrilintide and retatrutide Some researchers start with one compound and switch to the other based on their experience
While there is some evidence to suggest that GLP-1 agonists may have health benefits beyond their approved use for type 2 diabetes and obesity, non-diabetics should not take these medications without a prescription and guidance from a healthcare professional